Maximizing Options to Advance Informed Choice for HIV Prevention
Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a five-year (2021-2026) global project funded by the US President’s Emergency Plan for AIDS Relief (PEPFAR) through the US Agency for International Development (USAID) to help women prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products. To learn more about MOSAIC, click here.
The CATALYST Study
Catalyzing Access to New Prevention Products to Stop HIV (CATALYST) is MOSAIC’s flagship product introduction study. The study will provide and assess an enhanced service delivery package that includes oral PrEP, PrEP ring, and injectable cabotegravir. The package of products and services for PrEP will be provided to cis-gender women at PEPFAR/USAID delivery sites in Kenya, Lesotho, South Africa, Uganda, and Zimbabwe. The CATALYST study will also use quality improvement methods to refine the program and identify a core package for delivering PrEP choice. More information on this study will be available here as this project continues.
Global Tools and Resources
A new version of PrEP-it is now live at https://PrEPitWeb.org. PrEP-it is designed to support planning, implementation, monitoring and evaluation of PrEP delivery. Key features of PrEP-it include setting national and subnational targets, estimating costs and impact associated with targets, monitoring PrEP initiation, and forecasting drug supply needs.
Template Guidelines for Oral PrEP and Ring
These adaptable guidelines can be used to support the development and adoption of national guidelines that align with WHO PrEP guidance, including recommendations for daily and event-driven oral PrEP and the monthly PrEP ring. The document includes prompts for national-level consideration during the guideline adaptation process.
Post-Exposure Prophylaxis (PEP) Policy Synthesis Brief
This brief summarizes the PEP policy landscape, how to address barriers to policy and implementation, and provides recommendations to increase PEP uptake as part of HIV prevention. While it focuses on countries within the MOSAIC consortium, the findings are broadly applicable for ministries of health, implementing partners, providers, and potential PEP users alike.
These country-level analyses share key stakeholder perceptions of the ring in each country and are the product of consultations led by WHO, IPM, and MOSAIC during the period December 2021 – March 2022.
Eswatini Dapivirine Ring Messaging & Positioning Report
The Busara Centre for Behavioral Economics carried out market research on communication strategies for the PrEP ring in Eswatini in partnership with IPM and FHI 360 in 2021-2022. The resulting report recommends 12 communication strategies for positioning the PrEP ring in Eswatini, along with a description of the Eswatini context and population segments likely to take up the ring.
Drug Resistance Monitoring
MOSAIC HIV Drug Resistance Monitoring Program
MOSAIC’s HIV Drug Resistance (HIVDR) Monitoring Program monitors HIVDR in PrEP seroconverters in project-based and national roll-out programs in sub-Saharan Africa. The HIVDR Monitoring Toolkit can assist ministries of health, project implementers and policy makers develop HIVDR monitoring strategies and support the collection and testing of blood samples for HIVDR testing.